[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"site-content":3},{"home":4,"about":259,"team":340,"innovation":564,"kidneyCare":701,"contact":885,"nav":953},{"benefits":5,"healthCrisis":39,"hero":78,"joinTeam":95,"mission":118,"opt101":129,"press":174,"pressReleases":199,"seo":179,"teamImage":202,"treating":207},{"heading":6,"items":7},"Benefits",[8,14,19,24,29,34],{"_key":9,"_type":10,"icon":11,"text":12,"title":13},"kd","benefit","fast","Delivers rapid and sustained ultrafiltration across both day and night dwells.","Fast and consistent",{"_key":15,"_type":10,"icon":16,"text":17,"title":18},"ke","safer","Designed to minimize glucose spikes and metabolic distress.","Metabolically safer dialysis",{"_key":20,"_type":10,"icon":21,"text":22,"title":23},"kf","custom","Designing multiple concentrations to allow for highly personalized therapy.","Customizable osmotic strength",{"_key":25,"_type":10,"icon":26,"text":27,"title":28},"kg","protect","A gentler alternative that actively preserves the patient's residual kidney function.","Protects kidney function",{"_key":30,"_type":10,"icon":31,"text":32,"title":33},"kh","extended","Designed to prevent the peritoneal damage caused by glucose, extending the window for PD treatment.","Extended treatment duration",{"_key":35,"_type":10,"icon":36,"text":37,"title":38},"ki","flexibility","Empowers patients to safely manage their treatment at home, at work, or while traveling.","Greater flexibility and freedom",{"cta":40,"headingLine1":48,"headingLine2":49,"intro":50,"stats":51},{"_type":41,"emphasis":42,"link":43},"cta","primary",{"_type":44,"href":45,"label":46,"linkType":47},"link","\u002Fkidney-care","Understand kidney care","internal","A Health Crisis","Hiding in Plain Sight","Kidney disease affects millions of people worldwide, with many patients ultimately requiring dialysis.",[52,58,63,68,73],{"_key":53,"_type":54,"icon":55,"text":56,"title":57},"k2","stat","growth","Living with kidney disease worldwide—and growing ~8% per year.","850M+ Global Patients",{"_key":59,"_type":54,"icon":60,"text":61,"title":62},"k3","globe","Ranking among the top mortality drivers worldwide and still rising.","3rd Fastest-Growing Cause of Death",{"_key":64,"_type":54,"icon":65,"text":66,"title":67},"k4","chronic","Fueled globally by the rising rates of diabetes, hypertension, and obesity.","A Chronic & Progressive Disease",{"_key":69,"_type":54,"icon":70,"text":71,"title":72},"k5","spend","Consuming a massive portion of the healthcare budget to treat less than 1% of the population.","~7% of U.S. Medicare Spend",{"_key":74,"_type":54,"icon":75,"text":76,"title":77},"k6","innovation","The burden of disease has grown, but treatment technology has lagged for decades.","30+ Years Without Innovation",{"backgroundImage":79,"backgroundVideoUrl":87,"headingLine1":88,"headingLine2":89,"image":90,"intro":94},{"_type":80,"alt":81,"image":82},"media","Opterion — transforming dialysis care",{"_type":83,"asset":84},"image",{"_ref":85,"_type":86},"image-a47c9ae6ed55bacbbec728da2bccd191426410da-1857x1053-jpg","reference","https:\u002F\u002Fopterion.b-cdn.net\u002Fopterion hero.mp4","Transforming","dialysis care",{"_type":80,"alt":81,"image":91},{"_type":83,"asset":92},{"_ref":93,"_type":86},"image-1ddf0be52cd6b0889c0bc6e08ee57aa21a42a368-1036x1312-avif","Pioneering a non-glucose-based dialysis solution designed to make treatment safer, longer-lasting, and more personalized.",{"body":96,"cta":108,"heading":112,"image":113},[97],{"_key":98,"_type":99,"children":100,"markDefs":106,"style":107},"kj","block",[101],{"_key":102,"_type":103,"marks":104,"text":105},"kk","span",[],"We are always looking for dedicated and curious individuals who want to contribute to our mission of advancing breakthrough therapies for patients with chronic kidney disease. Join us and be part of our pioneering spirit.",[],"normal",{"_type":41,"emphasis":42,"link":109},{"_type":44,"href":110,"label":111,"linkType":47},"\u002Fcareers","View Open Roles","Join us and be part of our team",{"_type":80,"alt":114,"image":115},"Join the Opterion team",{"_type":83,"asset":116},{"_ref":117,"_type":86},"image-2131e7b519adcbc65a85bbbc443c8602ac18cd81-4096x2731-png",{"body":119,"heading":128},[120],{"_key":121,"_type":99,"children":122,"markDefs":127,"style":107},"k0",[123],{"_key":124,"_type":103,"marks":125,"text":126},"k1",[],"At Opterion, our mission is to relentlessly innovate for those living with chronic kidney disease, creating breakthrough therapies that put patients first — because every person deserves a future free from the burdens of outdated treatments.",[],"Our Mission",{"body":130,"cta":139,"glanceHeading":143,"glanceItems":144,"heading":168,"productImage":169},[131],{"_key":132,"_type":99,"children":133,"markDefs":138,"style":107},"kb",[134],{"_key":135,"_type":103,"marks":136,"text":137},"kc",[],"OPT101 is a novel, non-glucose-based osmotic agent designed to address the significant limitations of current PD therapies – improving outcomes and quality of life for patients with advanced chronic kidney disease (CKD).",[],{"_type":41,"emphasis":42,"link":140},{"_type":44,"href":141,"label":142,"linkType":47},"\u002Finnovation","See our treatment","At glance",[145,151,155,159,163],{"_key":146,"_type":147,"icon":148,"text":149,"wide":150},"glance0","glanceItem","glucose","Reduces glucose-related complications",false,{"_key":152,"_type":147,"icon":153,"text":154,"wide":150},"glance1","metabolic","Designed for fewer metabolic side effects",{"_key":156,"_type":147,"icon":157,"text":158,"wide":150},"glance2","safe","Designed to be a well-tolerated long-term treatment",{"_key":160,"_type":147,"icon":161,"text":162,"wide":150},"glance3","dwells","Designed for all daily dwells",{"_key":164,"_type":147,"icon":165,"text":166,"wide":167},"glance4","calendar","Program progressing, with first data anticipated in mid-2026",true,"Introducing OPT101",{"_type":80,"alt":170,"image":171},"OPT101 peritoneal dialysis solution",{"_type":83,"asset":172},{"_ref":173,"_type":86},"image-889c588167e843a0788ca9df0f4532601a02cd63-2048x2048-png",[175,182,188,194],{"_id":176,"externalUrl":177,"publishedAt":178,"slug":179,"summary":180,"title":181},"8cff7811-b7bf-442a-aee3-b78463062cad","https:\u002F\u002Fwww.globenewswire.com\u002Fnews-release\u002F2026\u002F09\u002F22\u002F3365973\u002F0\u002Fen\u002Fopterion-health-announces-positive-phase-1-results-for-opt101-supporting-advancement-to-phase-2a.html","2026-09-22",null,"SPARC study achieved all its objectives, establishing a strong clinical foundation for a differentiated, non-glucose-based treatment for peritoneal dialysis","Opterion Health Announces Positive Phase 1 Results for OPT101, Supporting Advancement to Phase 2a",{"_id":183,"externalUrl":184,"publishedAt":185,"slug":179,"summary":186,"title":187},"press.leadership-team","https:\u002F\u002Fwww.globenewswire.com\u002Fnews-release\u002F2026\u002F02\u002F23\u002F3242320\u002F0\u002Fen\u002Fopterion-health-ag-announces-first-patient-enrolled-in-phase-1-sparc-trial-following-cta-approval-for-opt101.html?_gl=1*gsipj2*_up*MQ..*_ga*MTYzNzgwOTAxMy4xNzg2NTU1NTcx*_ga_B6167QB2TF*czE3ODY1NTU1NzEkbzEkZzAkdDE3ODY1NTU1NzEkajYwJGwwJGgxMTYxNTE4Mzkw*_ga_ERWPGTJ5X8*czE3ODY1NTU1NzEkbzEkZzAkdDE3ODY1NTU1NzEkajYwJGwwJGgw","2026-02-23","Opterion Health AG Announces First Patient enrolled in Phase 1 SPARC Trial Following CTA Approval for OPT101","Opterion Health AG Announces First Patient enrolled in Phase 1 SPARC Trial",{"_id":189,"externalUrl":190,"publishedAt":191,"slug":179,"summary":192,"title":193},"press.ip-protection","https:\u002F\u002Fwww.globenewswire.com\u002Fnews-release\u002F2025\u002F09\u002F17\u002F3151371\u002F0\u002Fen\u002Fopterion-health-ag-submits-clinical-trial-application-for-first-in-human-study-of-opt101-in-patients-with-advanced-chronic-kidney-disease.html?_gl=1*czwsre*_up*MQ..*_ga*MTYzNzgwOTAxMy4xNzg2NTU1NTcx*_ga_B6167QB2TF*czE3ODY1NTU1NzEkbzEkZzAkdDE3ODY1NTU1NzEkajYwJGwwJGgxMTYxNTE4Mzkw*_ga_ERWPGTJ5X8*czE3ODY1NTU1NzEkbzEkZzAkdDE3ODY1NTU1NzEkajYwJGwwJGgw","2025-09-17","Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101 in Patients with Advanced Chronic Kidney Disease","Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101",{"_id":195,"externalUrl":196,"publishedAt":197,"slug":179,"summary":198,"title":198},"29460c6a-da4f-4dab-aa46-d2e81b6892b7","https:\u002F\u002Fwww.globenewswire.com\u002Fnews-release\u002F2025\u002F06\u002F23\u002F3103104\u002F0\u002Fen\u002Fopterion-health-ag-appoints-industry-leaders-rice-powell-and-mark-hahn-to-board-of-directors.html?_gl=1*1k08fec*_up*MQ..*_ga*MTYzNzgwOTAxMy4xNzg2NTU1NTcx*_ga_B6167QB2TF*czE3ODY1NTU1NzEkbzEkZzAkdDE3ODY1NTU1NzEkajYwJGwwJGgxMTYxNTE4Mzkw*_ga_ERWPGTJ5X8*czE3ODY1NTU1NzEkbzEkZzAkdDE3ODY1NTU1NzEkajYwJGwwJGgw","2025-06-23","Opterion Health AG Appoints Industry Leaders Rice Powell and Mark Hahn to Board of Directors",{"heading":200,"intro":201},"Latest Press Releases","Stay up to date with our most recent announcements and development milestones.",{"_type":80,"alt":203,"image":204},"The Opterion Team",{"_type":83,"asset":205},{"_ref":206,"_type":86},"image-e460b2dd3d121a46aeb854d3da8a9c0e691ba18f-2880x1920-avif",{"body":208,"cta":251,"heading":253,"image":254},[209,226],{"_key":210,"_type":99,"children":211,"markDefs":225,"style":107},"k7",[212,216,221],{"_key":213,"_type":103,"marks":214,"text":215},"k8",[],"For people living with chronic kidney disease, treatment options are limited and life-altering. Improving ",{"_key":217,"_type":103,"marks":218,"text":220},"254bd6981fdc",[219],"strong","Peritoneal Dialysis (PD) represents a compelling opportunity to enhance patients' lives",{"_key":222,"_type":103,"marks":223,"text":224},"e85206f5fcf2",[]," while enabling a scalable, cost-effective model for healthcare systems.",[],{"_key":227,"_type":99,"children":228,"markDefs":250,"style":107},"k9",[229,233,237,241,245],{"_key":230,"_type":103,"marks":231,"text":232},"ka",[],"Most patients rely on in-center hemodialysis, which is time-consuming, physically demanding, and highly disruptive to daily life. While Peritoneal Dialysis (PD) offers a gentler, at-home alternative linked to better early outcomes, ",{"_key":234,"_type":103,"marks":235,"text":236},"5148a0a5ebb4",[219],"it has seen little innovation in decades",{"_key":238,"_type":103,"marks":239,"text":240},"10eb4df4dfab",[],". Today's PD is constrained by ",{"_key":242,"_type":103,"marks":243,"text":244},"4cd0eadc839b",[219],"outdated, glucose-based solutions that cause metabolic stress and limit long-term use",{"_key":246,"_type":103,"marks":247,"text":249},"9453cf8e38d7",[248,219],"em",".",[],{"_type":41,"emphasis":42,"link":252},{"_type":44,"href":45,"label":46,"linkType":47},"Treating Kidney Disease",{"_type":80,"alt":255,"image":256},"Chronic kidney disease",{"_type":83,"asset":257},{"_ref":258,"_type":86},"image-df184cee0cfed1f4acc365ac65c1d48fadbaa210-744x744-png",{"_createdAt":260,"_id":261,"_rev":262,"_system":263,"_type":261,"_updatedAt":266,"cta":267,"hero":278,"jobItems":286,"openRoles":287,"team":290,"values":295,"vision":323},"2026-07-14T16:42:32Z","aboutPage","LPc3Jmv1ULU5uXF5HSD5an",{"base":264},{"id":261,"rev":265},"56Aw9PqdKBoWxRYUBzpq7z","2026-08-24T09:29:14Z",{"button":268,"eyebrow":271,"heading":272,"image":273},{"_type":41,"emphasis":269,"link":270},"secondary",{"_type":44,"href":141,"label":142,"linkType":47},"A Safer Future for Dialysis","Discover how OPT101 aims to make treatment gentler, more consistent, and metabolically safer.",{"_type":80,"alt":274,"image":275},"OPT101 solution",{"_type":83,"asset":276},{"_ref":277,"_type":86},"image-752a21c000088ffe84d875904035a0d663519ec7-1240x1240-jpg",{"heading":279,"image":280,"intro":285},"About Opterion",{"_type":80,"alt":281,"image":282},"The Opterion team",{"_type":83,"asset":283},{"_ref":284,"_type":86},"image-98a3bc7087d6e5ddad05a83c48ace3d6ef8a32d5-2560x1707-avif","Working tirelessly to build a well-tolerated, smarter, non-glucose-based dialysis solutions for millions of patients worldwide.",[],{"heading":288,"intro":289},"Interested in joining?","We're growing and always looking for exceptional people who want to improve the future of dialysis.",{"heading":291,"hiddenGroups":292,"intro":294},"Our team",[293],"operations","Our management team and board combine decades of experience in global pharma, dialysis, and biotechnology — including successful exits, clinical development programs, and product approvals.",{"heading":296,"items":297},"Our Values",[298,304,308,313,318],{"_key":299,"_type":300,"icon":301,"text":302,"title":303},"k1n","value","compassion","We approach every patient with empathy and respect, guiding how we innovate and care.","Compassion",{"_key":305,"_type":300,"icon":75,"text":306,"title":307},"k1o","We pursue bold solutions to transform a field that has seen little progress for decades.","Innovation for Lasting Impact",{"_key":309,"_type":300,"icon":310,"text":311,"title":312},"k1p","patient","We design every solution around real patient needs, outcomes, and long-term quality of life.","Patient-centered",{"_key":314,"_type":300,"icon":315,"text":316,"title":317},"k1q","teamwork","We act with transparency and trust, working together toward shared goals.","Integrity & Teamwork",{"_key":319,"_type":300,"icon":320,"text":321,"title":322},"k1r","quality","Built on Swiss precision, we develop reliable solutions designed for global impact.","Swiss Quality",{"body":324,"heading":333,"image":334,"subheading":339},[325],{"_key":326,"_type":99,"children":327,"markDefs":332,"style":107},"k1l",[328],{"_key":329,"_type":103,"marks":330,"text":331},"k1m",[],"Our mission is to relentlessly innovate for those living with chronic kidney disease, creating breakthrough therapies that put patients first, because every person deserves a future free from the burdens of outdated treatments.",[],"Our Vision and Mission",{"_type":80,"alt":335,"image":336},"A family together",{"_type":83,"asset":337},{"_ref":338,"_type":86},"image-e8139f21223ec76b1b2fdf2161db2c8ba3f65de9-1440x960-avif","Transform dialysis care and set a new Gold Standard in Peritoneal Dialysis.",[341,359,377,393,410,427,443,458,483,499,514,530,547],{"bio":342,"credentials":351,"group":352,"id":353,"name":354,"photo":355,"role":358},[343],{"_key":344,"_type":99,"children":345,"markDefs":350,"style":107},"2666b2cf2f4c",[346],{"_key":347,"_type":103,"marks":348,"text":349},"531d39f203a6",[],"David Ebsworth has served as Chairman of Opterion Health since December 2016. David has over 40 years of experience in the pharmaceutical, healthcare and biotech sectors. He is the former CEO of Galenica, Vifor Pharma as well as Oxford GlycoSciences, and previously lead the global pharmaceutical division of Bayer. David has chaired numerous public and private companies and has held board positions across audit, remuneration and governance committees. He currently serves as Chairman of Verona Pharma – which achieved a valuation of USD 8 billion following the successful US launch of Ohtuvayre for the treatment of COPD. He also serves as Chairman of Actimed Therapeutics.",[],"PhD","board","team.david-ebsworth","David Ebsworth",{"_type":83,"asset":356},{"_ref":357,"_type":86},"image-916e49cc6c11e4d026681afdccb43f216d785c0e-1168x1168-avif","Chairman of the Board of Directors",{"bio":360,"credentials":369,"group":370,"id":371,"name":372,"photo":373,"role":376},[361],{"_key":362,"_type":99,"children":363,"markDefs":368,"style":107},"4d38ab3a2078",[364],{"_key":365,"_type":103,"marks":366,"text":367},"55852c4e99ec",[],"Peter Reinemer was appointed as Chief Executive Officer of Opterion in February 2023, having served as CTO since June 2021. He brings over 30 years of international experience in the pharmaceutical and biotechnology sectors. Peter began his career at Bayer Pharma, where he spent over a decade in drug discovery research roles with increasing responsibility in Germany and Japan. He went on to hold senior executive positions at Proteros, a drug discovery services company based in Munich and Boston. Peter also co-founded IMD Natural Solutions, the developer of the natural preservative agent Nagardo®, which was acquired by Lanxess AG in 2017. Peter holds a master’s degree in chemistry, a PhD in Structural Biology from the Max Planck Institute for Biochemistry and the Technical University of Munich under Prof. Dr. Robert Huber, as well as an MBA.",[],"PhD, MBA","management","team.peter-reinemer","Peter Reinemer",{"_type":83,"asset":374},{"_ref":375,"_type":86},"image-2d293df71a4e164bf17f871a2043d45206c5ebcb-1168x1168-avif","Chief Executive Officer",{"bio":378,"credentials":351,"group":370,"id":387,"name":388,"photo":389,"role":392},[379],{"_key":380,"_type":99,"children":381,"markDefs":386,"style":107},"59408a3cffad",[382],{"_key":383,"_type":103,"marks":384,"text":385},"51fb8053125d",[],"Guido Grenzmann is the founder of Opterion and brings more than 30 years of experience in pharmaceutical research and development as well as IP and project management. Following his academic work focused on bacterial and viral protein synthesis, he held senior scientific roles in the biopharmaceutical industry including Group Leader for Molecular Biology and Genomics at Pfizer and Director of Biochemistry \u002F Gene Profiling at Altana Pharma, where he did research in inflammatory and respiratory diseases. In 2007 he founded PBS PharmaBioServices providing contract research and consulting with a focus on inflammatory diseases across multiple therapeutic domains. In 2012, driven by a vision to reduce the side effects associated with dialysis (PD), Guido founded Opterion, to develop an innovative peritoneal dialysis (PD) solution that could improve outcomes for patients undergoing this promising therapy.",[],"team.guido-grentzmann","Guido Grentzmann",{"_type":83,"asset":390},{"_ref":391,"_type":86},"image-d8f2da7eadc0e82bb8b3eb44068635f37cce9371-1168x1168-avif","Chief Scientific Officer \u002F Founder",{"bio":394,"credentials":403,"group":352,"id":404,"name":405,"photo":406,"role":409},[395],{"_key":396,"_type":99,"children":397,"markDefs":402,"style":107},"bf5f024401f8",[398],{"_key":399,"_type":103,"marks":400,"text":401},"1b24861d61dc",[],"Rice Powell has extensive experience in healthcare leadership, particularly in dialysis and renal care. He was Chairman of the Management Board of Fresenius Medical Care AG & Co. KGaA from 2013 to 2022, following a progression of senior roles including CEO of Fresenius Medical Care North America. He also held leadership positions at Biogen, Ergo Science, and Baxter Healthcare Corporation. Rice holds a Bachelor of Science in Biology from Mississippi College and contributes deep strategic and operational insight to Opterion Health.",[],"BSc","team.rice-powell","Rice Powell",{"_type":83,"asset":407},{"_ref":408,"_type":86},"image-1431f65024c963ecc1e35d9bd0200edd862fcc34-1168x1168-avif","Vice Chairman",{"bio":411,"credentials":420,"group":370,"id":421,"name":422,"photo":423,"role":426},[412],{"_key":413,"_type":99,"children":414,"markDefs":419,"style":107},"ff96b24b21d1",[415],{"_key":416,"_type":103,"marks":417,"text":418},"b931dae47c8c",[],"Michelle Mauri joined Opterion in 2025 as Corporate Matters and Business Operations Manager and currently serves as Chief Financial Officer. She brings over 15 years of international finance experience across both corporate and advisory roles in the United States and Switzerland. Before joining Opterion, she held senior positions at KPMG in Basel and at several high-growth, venture-backed companies in California, including NatureBox and Rocket Lawyer. A US Certified Public Accountant, Michelle is highly experienced in US GAAP and IFRS, SOX compliance, internal controls, and strategic financial planning. She holds a BS in Management with a minor in Accounting from California State University East Bay and is based in Basel, where she is also Treasurer for the American Women's Club Basel.",[],"CPA","team.michelle-mauri","Michelle Mauri",{"_type":83,"asset":424},{"_ref":425,"_type":86},"image-10e9a05687e01114cd6d809714ea65f6bde0a892-1168x1168-avif","Chief Financial Officer",{"bio":428,"credentials":351,"group":352,"id":437,"name":438,"photo":439,"role":442},[429],{"_key":430,"_type":99,"children":431,"markDefs":436,"style":107},"d241f21b5915",[432],{"_key":433,"_type":103,"marks":434,"text":435},"2a3c84ecbec1",[],"Ricardo Cordero served as Vice Chairman of Opterion Health from 2016 until 2025 and now serves as Board Member, bringing more than 3 decades of experience in the financial services industry. His past leadership roles include CEO of BZ Bank, Managing Partner at Reichmuth & Co Investmentfonds AG, co-founder and co-CEO at BWO Bank. A passionate and seasoned private Swiss investor, Ricardo maintains a broad investment portfolio spanning life sciences, technology and premium consumer goods.",[],"team.ricardo-cordero","Ricardo Cordero",{"_type":83,"asset":440},{"_ref":441,"_type":86},"image-74ec6b9ed18b3269670be1838d6f987cb4e7fe58-1168x1168-avif","Board Member",{"bio":444,"credentials":351,"group":352,"id":453,"name":454,"photo":455,"role":442},[445],{"_key":446,"_type":99,"children":447,"markDefs":452,"style":107},"7ce0c912baec",[448],{"_key":449,"_type":103,"marks":450,"text":451},"7af3861ddcf7",[],"Jan-Anders Karlsson has over 40 years of global leadership experience in the pharma and biotech industries, including executive roles in Europe, Asia and the US. Jan-Anders was a founder and CEO of Reset Pharmaceuticals Inc, and previously served as CEO of NASDAQ-listed Verona Pharma, leading the development of the first novel COPD treatment for 20 years from start to pivotal studies. As CEO of S*BIO Pte Ltd, he led the discovery and development of Vonjo (pacritinib), a now FDA approved treatment for myelofibrosis. His early career includes Head of Pharma Global Research at Bayer Healthcare AG and senior roles in, Rhone-Poulenc Rorer and Astra AB. Jan-Anders received a doctorate in Medical Science in Clinical Experimental Pharmacology from the University of Lund, Sweden.",[],"team.jan-anders-karlsson","Jan-Anders Karlsson",{"_type":83,"asset":456},{"_ref":457,"_type":86},"image-a1a9e103a141c3cff75c8f970dbc234bf55ad7d6-1168x1168-avif",{"bio":459,"credentials":476,"group":370,"id":477,"name":478,"photo":479,"role":482},[460,468],{"_key":461,"_type":99,"children":462,"markDefs":467,"style":107},"b0b89e70da0d",[463],{"_key":464,"_type":103,"marks":465,"text":466},"787edf609141",[],"Maxim Voropaiev joined Opterion in November 2023 as Chief Medical Officer. He brings 20 years of international experience in the pharmaceutical industry, having held global, strategic roles with increasing responsibility across clinical development, medical affairs, and statistics.",[],{"_key":469,"_type":99,"children":470,"markDefs":475,"style":107},"694919af931b",[471],{"_key":472,"_type":103,"marks":473,"text":474},"176c7fee9d1e",[],"Maxim has worked across a broad range of therapeutic areas – including oncology, kidney disease, gastroenterology, autoimmune and inflammatory diseases, neurology and respiratory conditions – for leading companies such as Novartis, CSL Vifor, and Bayer. With a strong focus on clinical trial design and execution, he brings a unique combination of medical insight and operational leadership. Maxim holds a medical doctor degree and a master degree (MAS) in statistics.",[],"MD, MAS","team.maxim-voropaiev","Maxim Voropaiev",{"_type":83,"asset":480},{"_ref":481,"_type":86},"image-927801b1682a3749f7635c968a2cb907cb5c439e-1168x1168-avif","Chief Medical Officer",{"bio":484,"credentials":369,"group":370,"id":493,"name":494,"photo":495,"role":498},[485],{"_key":486,"_type":99,"children":487,"markDefs":492,"style":107},"2dd7bbaa7f39",[488],{"_key":489,"_type":103,"marks":490,"text":491},"c57b4e89ea39",[],"Marc Willuhn joined Opterion in January 2023 as Head of CMC. Marc brings over 20 years of experience in drug development for global markets, with an outstanding track record in pharmaceutical product development that has led to multiple approved products. Marc held senior leadership positions at Fresenius Kabi and Baxter Healthcare before founding his own consultancy in 2018, providing technical and strategic consulting services to life sciences companies. He holds a master’s degree in chemistry from the Gerhard-Mercator-University in Duisburg, Germany, a PhD in organic chemistry from the Max-Planck-Institute for Coal Research in Mülheim an der Ruhr, Germany, and completed postdoctoral studies at the Faculté de Pharmacie in Paris, France. Marc also holds an MBA.",[],"team.marc-willuhn","Marc Willuhn",{"_type":83,"asset":496},{"_ref":497,"_type":86},"image-d7c5fe2d8a4fa67da7c825bfd47d051c9d890b54-1168x1168-avif","Head of CMC \u002F Manufacturing",{"bio":500,"credentials":420,"group":352,"id":509,"name":510,"photo":511,"role":442},[501],{"_key":502,"_type":99,"children":503,"markDefs":508,"style":107},"d22642fd73f2",[504],{"_key":505,"_type":103,"marks":506,"text":507},"e3b4cb6cbcc6",[],"Mark Hahn is an accomplished biotech executive with over two decades of financial leadership in the life sciences sector including at Cempra, Inc, Dova Pharmaceuticals and, currently Verona Pharma (NASDAQ: VRNA). His expertise spans corporate strategy, public and private debt, equity and royalty financings, IPO execution and M&A transactions. As CFO, Mark has led Verona Pharma through clinical development and the successful commercial launch of Verona’s first product, Ohtuvayre.",[],"team.mark-hahn","Mark Hahn",{"_type":83,"asset":512},{"_ref":513,"_type":86},"image-85083d710730ff98ede6c04a59d680635c212825-1168x1168-avif",{"bio":515,"credentials":351,"group":370,"id":524,"name":525,"photo":526,"role":529},[516],{"_key":517,"_type":99,"children":518,"markDefs":523,"style":107},"13358534a64a",[519],{"_key":520,"_type":103,"marks":521,"text":522},"ccb8d52b8217",[],"Ulrike Grimm joined Opterion in June 2020 to build and lead project excellence across its development program. Ulrike began her career as a sales representative for Sanol Pharma before joining Merck KGaA in 1997, where she progressed through roles of increasing responsibility starting as team leader for R&D projects and later as product leader for the company’s second commercial oncology drug. Between 2007 and 2010 Ulrike served as Vice President of Project and Portfolio Management at Fresenius Biotech. She went on to join Vifor Pharma in 2010, where she spent eight years as Vice President for Project and Alliance Management as well as Clinical Operations. In 2019 Ulrike started her own consulting company Pro2S AG, through which she continues to advise companies in the life sciences sector. Ulrike is an IPMA-certified Portfolio Management Director.",[],"team.ulrike-grimm","Ulrike Grimm",{"_type":83,"asset":527},{"_ref":528,"_type":86},"image-7d5917d1ba11f77a6a4bed7cc10e890d6e6e8780-1168x1168-avif","Chief Development Office, Head of PM & Regulatory",{"bio":531,"credentials":540,"group":370,"id":541,"name":542,"photo":543,"role":546},[532],{"_key":533,"_type":99,"children":534,"markDefs":539,"style":107},"523cb1c598c4",[535],{"_key":536,"_type":103,"marks":537,"text":538},"b40c9661f322",[],"Mylène Fleurant joined Opterion in July 2021 as Head of Quality, bringing over 20 years of experience in leading quality (QA) within the life sciences industry. She spent a decade as Region Head Quality Europe at Novartis and played a key role in implementing global quality systems at Merck Serono. Before founding her own consulting company in 2019, she served as Global Head of QA at Novimmune and Vice President of Quality Affairs at Alvotech. Mylène is a trained chemical engineer and holds a master’s degree from the University of Sherbrooke in Canada, as well as a degree in Quality Assurance Management from L’Ecole de Technologie Supérieure at the University of Quebec.",[],"MSc","team.mylene-fleurant","Mylène Fleurant",{"_type":83,"asset":544},{"_ref":545,"_type":86},"image-2ea475864600ff3e27258da6ef52f25f8362fe31-1168x1168-avif","Head of Quality Assurance",{"bio":548,"credentials":557,"group":370,"id":558,"name":559,"photo":560,"role":563},[549],{"_key":550,"_type":99,"children":551,"markDefs":556,"style":107},"b1119d9fe8b0",[552],{"_key":553,"_type":103,"marks":554,"text":555},"ec871687abbb",[],"Daniel Lustenberger, who previously served as Chief Financial Officer of Opterion, assumed the role of Senior Vice President Corporate Development China. This move reflects his extensive experience in scaling businesses and cross-border operations in the Asia Pacific region and China in particular. Daniel brings more than two decades of leadership and consulting experience gained in senior positions at multinational companies such as DKSH, CSL Vifor and PwC. For over 20 years, Daniel has supported scaling up companies with significant growth or transformation. His long-standing involvement in the Asia Pacific markets positions him ideally to lead Opterion’s corporate development in China and beyond.",[],"CPA, EMBA","team.daniel-lustenberger","Daniel Lustenberger",{"_type":83,"asset":561},{"_ref":562,"_type":86},"image-d7653da5e68940491f8beefd37d8add6a9f4b305-1168x1168-avif","Corporate Development China",{"_createdAt":260,"_id":565,"_rev":566,"_system":567,"_type":565,"_updatedAt":570,"clinicalTrials":571,"lifestyle":606,"market":611,"opportunity":636,"productScroll":655,"whyInvest":668},"innovationPage","Y5NPXgWhbvM793fLbmtrDN",{"base":568},{"id":565,"rev":569},"13szLHQ71QeyqE1XioC8nu","2026-08-15T12:52:36Z",{"currentStageLogo":572,"heading":577,"intro":578,"stages":579},{"_type":80,"alt":573,"image":574},"SPARC — It's time to talk PD",{"_type":83,"asset":575},{"_ref":576,"_type":86},"image-ac5255a7f04739806b1c2d3e0474cd4c49c20c9e-720x178-avif","Clinical Trials","Every new therapy goes through a series of well-defined clinical stages. OPT101 is moving through this pathway with a clear plan and strong scientific foundations.",[580,586,591,596,601],{"_key":581,"_type":582,"icon":583,"text":584,"title":585},"k2t","stage","assay","Safety and performance demonstrated in accepted models.","Preclinical",{"_key":587,"_type":582,"icon":588,"text":589,"title":590},"k2u","inbox","Regulatory application filed to begin first-in-human studies in Europe.","CTA Submitted",{"_key":592,"_type":582,"current":167,"icon":593,"text":594,"title":595},"k2v","doc","Last patient last visit completed! Our first study in humans focuses on safety and tolerability. A small group of participants received OPT101 to confirm it behaves as expected and is well-tolerated.","Phase 1",{"_key":597,"_type":582,"icon":598,"text":599,"title":600},"k2w","vial","After establishing safety, we evaluate how well OPT101 performs — identifying the optimal dose, measuring effectiveness, and providing the first clear signals of clinical benefit. A major value inflection point.","Phase 2",{"_key":602,"_type":582,"icon":603,"text":604,"title":605},"k2x","people","Large, multi-country studies confirm safety and effectiveness in a broad patient population. Positive Phase 3 results support regulatory approval and market entry.","Phase 3",{"_type":80,"alt":607,"image":608},"Patient living freely",{"_type":83,"asset":609},{"_ref":610,"_type":86},"image-dd3e4e87f49901e5366250ee66673b81df333307-2880x1920-jpg",{"heading":612,"image":613,"intro":618,"stats":619},"A large and growing market with limited innovation",{"_type":80,"alt":614,"image":615},"A growing global market",{"_type":83,"asset":616},{"_ref":617,"_type":86},"image-a71de6dd95c85cf821e2b548f1eb83c9f5597357-2880x1920-avif","Peritoneal dialysis represents a growing global market, driven by rising chronic disease and increasing demand for home-based treatment. Despite this, innovation has remained limited.",[620,626,631],{"_key":621,"_type":622,"label":623,"text":624,"value":625},"k2q","mStat","Market","PD represents a $10B market today","$10B",{"_key":627,"_type":622,"label":628,"text":629,"value":630},"k2r","by 2030","Projected to grow to $16B by 2030","$16B",{"_key":632,"_type":622,"label":633,"text":634,"value":635},"k2s","Years with no innovation","This is the first innovation of its kind in more than 30 years","+30",{"benefits":637,"heading":653,"intro":654},[638,641,644,647,650],{"_key":639,"_type":10,"text":640},"k2l","Reduces metabolic stress and insulin spikes",{"_key":642,"_type":10,"text":643},"k2m","Consistent fluid removal across all dwells",{"_key":645,"_type":10,"text":646},"k2p","Suitable for diabetic patients — 45% of the PD population, as well as being designed to prevent CKD patients from becoming diabetic while on treatment.",{"_key":648,"_type":10,"text":649},"k2o","Consistent performance across day and night treatments",{"_key":651,"_type":10,"text":652},"k2n","Removes the need for glucose-based osmotic agents","The first innovation of its kind in over 30 years","Peritoneal dialysis has relied on the same core approaches for decades. OPT101 introduces a fundamentally new solution that is designed to improve chronic kidney disease (CKD) therapy.",{"designedFor":656,"hevcUrl":660,"scene1Heading":661,"scene1Para1":662,"scene1Para2":663,"scene2Heading":664,"scene3Line1":665,"scene3Line2":666,"webmUrl":667},[657,658,33,659],"Reduced metabolic burden","Consistent performance","Personalized therapy options","https:\u002F\u002Fopterion.b-cdn.net\u002Fopterion bag_10sec_800px-hevc-safari.mp4","OPT101","A Non-Glucose-Based Breakthrough for Peritoneal Dialysis","Designed to address long-standing limitations in current dialysis treatment.","Designed for","An opportunity to redefine","a growing global treatment","https:\u002F\u002Fopterion.b-cdn.net\u002Fopterion bag_10sec_800px-vp9-chrome.webm",{"heading":669,"items":670,"subheading":700},"Why Invest in Opterion",[671,676,680,684,688,692,696],{"_key":672,"_type":673,"text":674,"title":675},"k2y","accItem","Kidney disease affects 850M+ people worldwide and is the 3rd fastest-growing cause of death, yet treatment has barely evolved in decades.","Huge unmet need",{"_key":677,"_type":673,"text":678,"title":679},"k2z","OPT101 removes glucose from the core of peritoneal dialysis — addressing the root cause of metabolic stress that limits current therapies.","First non-glucose-based osmotic driver for all daily dwells",{"_key":681,"_type":673,"text":682,"title":683},"k30","A robust and defensible intellectual property position protects the innovation and its commercial potential.","Strong IP protection",{"_key":685,"_type":673,"text":686,"title":687},"k31","Built on well-understood mechanisms and validated in accepted preclinical models, de-risking the path to the clinic.","High probability of success",{"_key":689,"_type":673,"text":690,"title":691},"k32","A scalable, home-based model that improves outcomes while lowering the cost burden on healthcare systems.","Attractive economics",{"_key":693,"_type":673,"text":694,"title":695},"k33","Clear strategic interest from dialysis incumbents and pharma, offering several routes to liquidity.","Multiple exit paths",{"_key":697,"_type":673,"text":698,"title":699},"k34","An experienced team with a history of building and delivering breakthrough medical innovations.","Leadership with proven track records","A differentiated opportunity in renal care",{"_createdAt":260,"_id":702,"_rev":703,"_type":702,"_updatedAt":704,"closing":705,"dialysis":710,"discover":754,"hero":761,"kidneyFunction":774,"landscape":799,"productVideo":804,"replace":807,"stats":812,"whyOpt101":857},"kidneyCarePage","h9RgWSv7SNE1Mfebd9Jafm","2026-08-03T14:44:27Z",{"_type":80,"alt":706,"image":707},"",{"_type":83,"asset":708},{"_ref":709,"_type":86},"image-077efc33e07c0f23f356ae373227b9710e2138e7-2880x1920-jpg",{"heading":711,"intro":712,"treatments":713},"How Dialysis Works Today","When the kidneys can no longer function, dialysis removes excess fluid and waste from the body. There are two primary approaches.",[714,735],{"_key":715,"_type":716,"cards":717,"title":734},"k2d","treatment",[718,722,726,730],{"_key":719,"_type":720,"icon":165,"text":721},"k25","dCard","Requires 3–5 hour clinic visits, 3x weekly",{"_key":723,"_type":720,"icon":724,"text":725},"k26","Confusion","Causes fatigue, cramps, headaches, and nausea",{"_key":727,"_type":720,"icon":728,"text":729},"k27","injection","Long-term vascular access issues",{"_key":731,"_type":720,"icon":732,"text":733},"k28","fi_dollar-sign","Costs $70–120K per patient annually in the U.S.","Hemodialysis (HD)",{"_key":736,"_type":716,"cards":737,"title":753},"k2e",[738,742,746,750],{"_key":739,"_type":720,"icon":740,"text":741},"k29","home-alt","Home-based, flexible, and gentler",{"_key":743,"_type":720,"icon":744,"text":745},"k2a","kidney","Better preserves kidney function",{"_key":747,"_type":720,"icon":748,"text":749},"k2b","medical_documentation","Higher first-year survival rates",{"_key":751,"_type":720,"icon":732,"text":752},"k2c","Significantly more cost-effective","Peritoneal Dialysis (PD)",{"button":755,"image":757},{"_type":41,"emphasis":42,"link":756},{"_type":44,"href":141,"label":142,"linkType":47},{"_type":80,"alt":170,"image":758},{"_type":83,"asset":759},{"_ref":760,"_type":86},"image-b18f2d6a2e60ff2ae03eb27d1c7be943719dc002-2048x2048-avif",{"heading":762,"image":763,"intro":768,"mobileImage":769},"Kidney Care Today",{"_type":80,"alt":764,"image":765},"Kidneys",{"_type":83,"asset":766},{"_ref":767,"_type":86},"image-6de4946b21e7d320df683c4224d5f78f4c395d0b-2048x2048-png","Understanding how kidney disease progresses and how dialysis supports patients.",{"_type":80,"alt":770,"image":771},"Illustration of human kidneys",{"_type":83,"asset":772},{"_ref":773,"_type":86},"image-ed2a7a6ceb8808af8eb8bfb9e5e52ee566b57a91-2048x2048-avif",{"cards":775,"heading":797,"intro":798},[776,782,787,792],{"_key":777,"_type":778,"icon":779,"text":780,"title":781},"k1s","funcCard","\u002Ficons\u002Fkidney-care\u002Finitial-slider\u002Ffi_edit.svg","Removing waste and excess fluid to keep the body clean","Filters the blood",{"_key":783,"_type":778,"icon":784,"text":785,"title":786},"k1t","\u002Ficons\u002Fkidney-care\u002Finitial-slider\u002FDropHalf.svg","Regulating water, salts and minerals so cells function properly","Maintains balance",{"_key":788,"_type":778,"icon":789,"text":790,"title":791},"k1u","\u002Ficons\u002Fkidney-care\u002Finitial-slider\u002Fblood_pressure_02.svg","Helping manage blood pressure and acid levels","Controls key systems",{"_key":793,"_type":778,"icon":794,"text":795,"title":796},"k1v","\u002Ficons\u002Fkidney-care\u002Finitial-slider\u002Fbones.svg","Producing hormones for red blood cells and bone health","Supports vital processes","What is the kidney and why does it matter?","The kidneys are essential for keeping the body in balance.\n\nWhen the kidneys stop working properly, these systems quickly fall out of balance, affecting the whole body, not just one organ.",{"body":800,"heading":801,"statLabel":802,"statValue":803},"Kidney disease is part of a broader global health shift driven by aging populations and rising chronic conditions such as diabetes, hypertension, and obesity. As these conditions increase, so does the number of patients requiring long-term care to replace essential kidney function.","The Landscape of Kidney Care","People affected worldwide","850,000,000+",{"hevcUrl":805,"webmUrl":806},"https:\u002F\u002Fopterion.b-cdn.net\u002Fkidney_15sec_800px-hevc-safari.mp4","https:\u002F\u002Fopterion.b-cdn.net\u002Fkidney_15sec_800px-vp9-chrome.webm",{"image":808,"statement":811},{"_type":80,"alt":170,"image":809},{"_type":83,"asset":810},{"_ref":760,"_type":86},"As kidney function declines, patients eventually require treatment to replace the role of the kidneys.",{"categories":813},[814,831,845],{"_key":815,"_type":816,"stats":817,"title":830},"k22","category",[818,824],{"_key":819,"_type":54,"icon":820,"label":821,"sub":822,"value":823},"k1w","earth","11th leading cause of death worldwide","fastest-growing cause of death","3rd",{"_key":825,"_type":54,"icon":826,"label":827,"sub":828,"value":829},"k1x","activity","Driven by diabetes, hypertension, and obesity","annual growth","4%","Kidney Disease",{"_key":832,"_type":816,"stats":833,"title":844},"k23",[834,839],{"_key":835,"_type":54,"icon":593,"label":836,"sub":837,"value":838},"k1y","Kidney Failure","patients","~25M",{"_key":840,"_type":54,"icon":841,"label":842,"sub":837,"value":843},"k1z","bandage","Treated ESRD",">2M","Disease Progression",{"_key":846,"_type":816,"stats":847,"title":856},"k24",[848,852],{"_key":849,"_type":54,"icon":850,"label":734,"value":851},"k20","hd","~88%",{"_key":853,"_type":54,"icon":854,"label":753,"value":855},"k21","pd","~12%","Treatment Split",{"heading":858,"items":859,"subheading":884},"OPT101 is designed to set a new standard of care",[860,864,868,872,876,880],{"_key":861,"_type":673,"text":862,"title":863},"k2f","OPT101 removes glucose from the core of peritoneal dialysis — addressing the root cause of metabolic stress in current therapies.","Glucose-free by design",{"_key":865,"_type":673,"text":866,"title":867},"k2g","By avoiding glucose, OPT101 reduces insulin spikes and metabolic burden, making it well suited for diabetic patients.","Safer metabolic profile",{"_key":869,"_type":673,"text":870,"title":871},"k2h","Delivers steady ultrafiltration across both day and night dwells, for more predictable therapy.","More consistent day and night",{"_key":873,"_type":673,"text":874,"title":875},"k2i","Adjustable concentrations allow therapy to be personalized to each patient.","Compatible with diverse patient needs",{"_key":877,"_type":673,"text":878,"title":879},"k2j","Designed to slot into existing PD workflows with minimal disruption for patients and providers.","Simple substitution for existing PD solutions",{"_key":881,"_type":673,"text":882,"title":883},"k2k","A scalable, home-based model that improves outcomes while easing pressure on healthcare systems.","Built for scalability and global impact","Designed to set a new standard of care",{"_createdAt":260,"_id":886,"_rev":887,"_system":888,"_type":886,"_updatedAt":891,"details":892,"hero":948,"jobs":952},"contactPage","SugKZFpQV1X8jTRLWa9yGp",{"base":889},{"id":886,"rev":890},"nXfR47JxO13AdXevvxOHfn","2026-10-03T08:23:38Z",{"blocks":893,"heading":947},[894,909,916,925,933],{"_key":895,"_type":896,"intro":897,"label":898,"links":899},"k3d","contactBlock","For investor inquiries, detailed materials, or direct contact with our leadership team:","Investor Relations",[900,905],{"_key":901,"_type":902,"href":903,"text":904},"k35","cLink","mailto:info@opterion.com","info@opterion.com",{"_key":906,"_type":902,"href":907,"text":908},"k36","tel:+41 61 551 71 83","+41 61 551 71 83",{"_key":910,"_type":896,"intro":911,"label":912,"links":913},"k3e","Journalists, analysts, and communications professionals can reach us at:","Media Contact",[914],{"_key":915,"_type":902,"href":903,"text":904},"k37",{"_key":917,"_type":896,"intro":918,"label":919,"links":920},"k3f","Please note that all official job posting will be published here and on our LinkedIn channel.","Careers",[921],{"_key":922,"_type":902,"href":923,"text":924},"k38","mailto:hr@opterion.com","hr@opterion.com",{"_key":926,"_type":896,"label":927,"links":928},"k3g","Social media",[929],{"_key":930,"_type":902,"href":931,"text":932},"k39","https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fopterion-health","LinkedIn",{"_key":934,"_type":896,"label":935,"links":936},"k3h","Location",[937,940,943],{"_key":938,"_type":902,"text":939},"k3a","Opterion Health AG",{"_key":941,"_type":902,"text":942},"k3b","Hofackerstrasse 40B, 4132 Muttenz, Switzerland",{"_key":944,"_type":902,"href":945,"text":946},"k3c","https:\u002F\u002Fmaps.google.com\u002F?q=Hofackerstrasse+40B+4132+Muttenz","Get directions","Contact Opterion",{"eyebrow":949,"generalEmail":904,"generalLabel":950,"heading":951},"Contact us","General inquiries","Contact us about Transforming Dialysis Care",{"heading":288,"intro":289},{"footerAddress":954,"footerColumns":955,"footerCta":980,"footerHeading":983,"headerCta":984,"headerLinks":987},"Opterion Health AG\nHofackerstrasse 40B, 4132 Muttenz, Switzerland",[956,969],{"links":957,"title":968},[958,961,964,966],{"externalUrl":179,"href":959,"label":960,"linkType":47,"openInNewTab":179},"\u002F","Home",{"externalUrl":179,"href":962,"label":963,"linkType":47,"openInNewTab":179},"\u002Fabout","About",{"externalUrl":179,"href":141,"label":965,"linkType":47,"openInNewTab":179},"Innovation",{"externalUrl":179,"href":45,"label":967,"linkType":47,"openInNewTab":179},"Kidney Care","Quick Links",{"links":970,"title":979},[971,974,977],{"externalUrl":179,"href":972,"label":973,"linkType":47,"openInNewTab":179},"\u002Fcontact","Contact Us",{"externalUrl":975,"href":179,"label":919,"linkType":976,"openInNewTab":150},"mailto:careers@opterion.com","external",{"externalUrl":978,"href":179,"label":932,"linkType":976,"openInNewTab":167},"https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fopterion-health\u002F","Contacts",{"emphasis":42,"link":981},{"externalUrl":179,"href":972,"label":982,"linkType":47,"openInNewTab":179},"Contact Investor Relations","Explore the Opterion Investment Opportunity",{"emphasis":42,"link":985},{"externalUrl":179,"href":972,"label":986,"linkType":47,"openInNewTab":179},"Request Details",[988,1000,1019,1036,1052,1055],{"hasMenu":167,"href":959,"label":960,"menu":989},{"desc":990,"items":991,"theme":998,"title":999,"to":959},"Our ambition is clear: transform dialysis care and set a new Gold Standard in Peritoneal Dialysis ",[992,995],{"icon":716,"label":993,"to":994},"The Treatment","\u002F#treating",{"icon":996,"label":6,"to":997},"benefits","\u002F#benefits","accent","Welcome to Opterion",{"hasMenu":167,"href":962,"label":963,"menu":1001},{"desc":1002,"items":1003,"theme":1018,"title":963,"to":962},"Opterion is building a safer, smarter, non-glucose-based dialysis solution",[1004,1007,1010,1014],{"icon":1005,"label":333,"to":1006},"eye","\u002Fabout#mission",{"icon":1008,"label":296,"to":1009},"trophy","\u002Fabout#values",{"icon":1011,"label":1012,"to":1013},"team","Our Team","\u002Fabout#team",{"icon":1015,"label":1016,"to":1017},"join","Join Us","\u002Fabout#jobs","purple",{"hasMenu":167,"href":141,"label":965,"menu":1020},{"desc":1021,"items":1022,"theme":1035,"title":965,"to":141},"Discover OPT101, a non-glucose-based innovation designed to improve dialysis outcomes.",[1023,1026,1029,1032],{"icon":1005,"label":1024,"to":1025},"The Opportunity","\u002Finnovation#opportunity",{"icon":996,"label":1027,"to":1028},"Market opportunity","\u002Finnovation#market",{"icon":1011,"label":1030,"to":1031},"Clinical trials","\u002Finnovation#trials",{"icon":1008,"label":1033,"to":1034},"Why invest","\u002Finnovation#why-invest","blue",{"hasMenu":167,"href":45,"label":967,"menu":1037},{"desc":768,"items":1038,"theme":1051,"title":967,"to":45},[1039,1042,1045,1048],{"icon":1005,"label":1040,"to":1041},"The landscape","\u002Fkidney-care#landscape",{"icon":996,"label":1043,"to":1044},"By the numbers","\u002Fkidney-care#stats",{"icon":1011,"label":1046,"to":1047},"How dialysis works","\u002Fkidney-care#dialysis",{"icon":1008,"label":1049,"to":1050},"Why OPT101","\u002Fkidney-care#why-opt","pink",{"hasMenu":150,"href":1053,"label":1054,"menu":179},"\u002F#press","Press",{"hasMenu":150,"href":972,"label":949,"menu":179}]